Research progress of biomarkers in the prediction of anti-PD-1/PD-L1 immunotherapeutic efficiency in lung cancer

Luyao Wang, Zongxing Yang, Fucheng Guo, Yurong Chen, Jiarui Wei, Xiangpeng Dai, Xiaoling ZhangFrontiers in Immunology 2023 · DOI

This review paper, published in Frontiers in Immunology, provides a comprehensive overview of the current landscape of biomarkers used to predict the efficacy of anti-PD-1/PD-L1 immunotherapies in lung cancer. It synthesizes findings from major clinical trials and mechanistic studies to categorize established and emerging predictors of patient response.

TL;DR

While anti-PD-1/PD-L1 therapies have revolutionized lung cancer treatment, only 20–25% of patients show a sustained response. This paper reviews the "biomarker toolkit"—ranging from tissue-based PD-L1 expression to "liquid biopsies" like ctDNA and even the gut microbiome—aimed at moving immunotherapy toward true precision medicine.

What Problem Does This Paper Address?

Lung cancer remains the leading cause of cancer-related deaths globally. Immune Checkpoint Inhibitors (ICIs), specifically those targeting the PD-1/PD-L1 axis, have significantly improved survival rates. However, the clinical challenge is patient selection.

Immunotherapy is expensive and can cause severe immune-related adverse events (irAEs). Because a majority of patients do not respond to monotherapy, clinicians need reliable biomarkers to predict who will benefit. The paper addresses the limitations of current standards (like PD-L1 IHC staining) and explores more dynamic, less invasive alternatives to guide treatment.

Methods

As a review article, the authors did not conduct new laboratory experiments. Instead, they performed a systematic synthesis of:

  • Clinical Trial Data: Analysis of landmark trials including the KEYNOTE (Pembrolizumab), CheckMate (Nivolumab), IMpower (Atezolizumab), and PACIFIC (Durvalumab) series.
  • Mechanistic Analysis: Reviewing how the PD-1/PD-L1 pathway facilitates tumor evasion and how resistance (primary and acquired) develops.
  • Biomarker Categorization: The authors organized biomarkers into three main "neighborhoods": tissue-based, peripheral blood-based (liquid biopsies), and microbial.

Datasets

The paper relies on the outcomes of large-scale, phase II and III clinical trial datasets. Key benchmarks mentioned include:

  • KEYNOTE-024: Evaluated Pembrolizumab in patients with high PD-L1 expression (TPS ≥50%).
  • CheckMate 017/057: Established Nivolumab as a second-line treatment.
  • PACIFIC Study: Focused on Durvalumab as maintenance therapy for stage III NSCLC.
  • Public Genomic Databases: References to studies using Whole Exome Sequencing (WES) to correlate Tumor Mutation Burden (TMB) with clinical outcomes.

Key Insights and Ideas

  • The PD-L1 Paradox: While high PD-L1 expression is the "gold standard" for prediction, it is imperfect. Some patients with 0% expression still respond, likely due to the spatial and temporal heterogeneity of the tumor—meaning a single needle biopsy might miss the "hot" part of the tumor.
  • TMB as a Proxy for "Foreignness": High Tumor Mutation Burden (TMB) leads to more neoantigens. Essentially, the more mutations a tumor has, the more "alien" it looks to the immune system, making it an easier target once the PD-1 "brakes" are removed.
  • The Rise of Liquid Biopsies: Peripheral blood biomarkers like circulating tumor DNA (ctDNA) and blood TMB (bTMB) are gaining ground. They are less invasive than traditional biopsies and may provide a more holistic view of the body's total tumor burden.
  • The Gut-Lung Axis: One of the more surprising insights is the role of the gut microbiome. The presence of specific bacteria (e.g., Akkermansia muciniphila) and short-chain fatty acids (SCFAs) can significantly modulate the systemic immune response, influencing whether a patient responds to ICIs.
  • Combination Strategies: The paper highlights a shift from monotherapy to "cocktails"—combining ICIs with chemotherapy, radiation, anti-angiogenic agents, or even CAR-T cell therapy to turn "cold" tumors "hot."

Key Results

The paper summarizes quantitative survival benefits across different drugs:

  • Nivolumab: In the CheckMate 017 trial, median Overall Survival (OS) was 9.2 months compared to 6.0 months with standard docetaxel chemotherapy.
  • Pembrolizumab: Naive patients in the KEYNOTE-024 trial reached a median OS of 22.3 months, a landmark result for immunotherapy.
  • Atezolizumab: The IMpower130 trial showed that combining Atezolizumab with chemotherapy improved median OS to 18.6 months.
  • Durvalumab: The PACIFIC study demonstrated that maintenance Durvalumab significantly improved Progression-Free Survival (PFS) in unresectable stage III patients.

Limitations and Future Work

The authors acknowledge several hurdles:

  • Standardization: There is a lack of uniformity in how TMB is calculated and what "cutoff" values define a "high" vs. "low" responder.
  • Tissue Heterogeneity: Traditional biopsies are "snapshots" that may not represent the entire tumor or how it changes over time.
  • Complexity of Resistance: Tumors can develop acquired resistance through pathways like B2M loss or IFN-gamma signaling mutations, which current biomarkers don't always capture early enough.
  • Future Direction: The authors suggest that the future lies in multi-modal prediction models—combining genomic, proteomic, and microbial data into a single "score" to provide a higher degree of predictive precision.

Summary updated

Abstract

Currently, anti-PD-1/PD-L1 immunotherapy using immune checkpoint inhibitors is widely used in the treatment of multiple cancer types including lung cancer, which is a leading cause of cancer death in the world. However, only a limited proportion of lung cancer patients will benefit from anti-PD-1/PD-L1 therapy. Therefore, it is of importance to predict the response to immunotherapy for the precision treatment of patients. Although the expression of PD-L1 and tumor mutation burden (TMB) are commonly used to predict the clinical response of anti-PD-1/PD-L1 therapy, other factors such as tumor-specific genes, dMMR/MSI, and gut microbiome are also promising predictors for immunotherapy in lung cancer. Furthermore, invasive peripheral blood biomarkers including blood DNA-related biomarkers (e.g., ctDNA and bTMB), blood cell-related biomarkers (e.g., immune cells and TCR), and other blood-related biomarkers (e.g., soluble PD-L1 and cytokines) were utilized to predict the immunotherapeutic response. In this review, the current achievements of anti-PD-1/PD-L1 therapy and the potential biomarkers for the prediction of anti-PD-1/PD-L1 immunotherapy in lung cancer treatment were summarized and discussed.
BibTeX
@inproceedings{wang2023research,
  author = {Luyao Wang and Zongxing Yang and Fucheng Guo and Yurong Chen and Jiarui Wei and Xiangpeng Dai and Xiaoling Zhang},
  title = {{Research progress of biomarkers in the prediction of anti-PD-1/PD-L1 immunotherapeutic efficiency in lung cancer}},
  booktitle = {Frontiers in Immunology},
  year = {2023},
  doi = {10.3389/fimmu.2023.1227797},
}
Figure